Call for Abstract

8th Annual Pharma Middle East Congress, will be organized around the theme “Challenges and Innovations in Pharmaceutical Sciences”

Pharma Middle East 2016 is comprised of 15 tracks and 110 sessions designed to offer comprehensive sessions that address current issues in Pharma Middle East 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

The science that deals with the origin, nature, chemistry, effects, and uses of drugs; it includes Pharmacognosy, Pharmacokinetics, Pharmacodynamics, Pharmacotherapeutics, and Toxicology. This session is dealt with many sub disciplines such as Clinical Pharmacology, Neuropharmacology, Psychopharmacology, Pharmacogenetics, Pharmacogenomics, Pharmacoepidemiology, Systems Pharmacology, Toxicology, Theoretical Pharmacology, Posology, Pharmacognosy, Behavioral Pharmacology, Environmental pharmacology, Dental Pharmacology, Medical Pharmacology, Endocrine pharmacology etc.,

The worldwide clinical trial imaging business sector is forecasted to reach $981.53 Million by 2020 from $724.87 Million in 2015, at a CAGR of 6.25%. R&D spending in Asia has significantly grown from $177 billion in 2003 to $329 billion in 2010, at a CAGR of 9.29%. 

  • Track 1-1Behavioral pharmacology
  • Track 1-2Cardiovascular Pharmacology
  • Track 1-3Cognitive neuroscience and neurosystems
  • Track 1-4Neuropsychology
  • Track 1-5Functional modes of the brain
  • Track 1-6Endocrine pharmacology
  • Track 1-7Clinical pharmacology
  • Track 1-8Pharmacokinetics
  • Track 1-9Medical Pharmacology
  • Track 1-10Ethnopharmacology and etc....

Biopharmaceutical science involves the creation of medical drugs by artificially growing some or all of their components. It is the pluridisciplinar background on the discovery phase of the drug development process, at advanced level. This field includes the study of molecular mechanisms of disease, potential therapeutic targets and therapeutic strategies. The Session discusses on recent trends in pharmaceutical research, in which increasing numbers of drugs are coming from large biopharmaceutical molecules. Bio-Pharmaceutical Sciences session includes talks on diversified fields like Biopharmaceutics and drug disposition, Innovations in clinical development, Pharmaceutical technology, Drug discovery and design, Pharmaceutics and drug delivery, Routes of administration, Fundamental drug development and etc....

The worldwide business market for Biopharmaceuticals was $70.1 billion in 2012 and $68.9 billion in 2013. This business sector is expected to ascend at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018. By a market report distributed by Persistence Market Research "Worldwide Market Study on Biopharmaceuticals: Asia is predicted to Witness Highest Growth by 2020", the worldwide biopharmaceuticals business sector was valued at US$ 162 Billion in 2014 and is forecasted to develop at a CAGR of 9.4% from 2014 to 2020, to achieve an expected estimation of US$ 278 Billion by 2020.

  • Track 2-1Biopharmaceutics and drug disposition
  • Track 2-2Innovations in clinical development
  • Track 2-3Pharmaceutical technology
  • Track 2-4Drug discovery and design
  • Track 2-5Pharmaceutics and drug delivery
  • Track 2-6Radiopharmaceuticals
  • Track 2-7Routes of administration
  • Track 2-8Fundamental drug development and etc....

Pharmacognosy is the study of medicines derived from natural sources. Most pharmacognostic studies focus on plants and medicines derived from plants, other types of organisms are also regarded as pharmacognostically interesting, in particular, various types of microbes (bacteria, fungi, etc.), and, recently, various marine organisms. This topic is dealt with topics like Medical Ethnobotany, Ethnopharmacology, Phytotherapy, Phytochemistry, Phytoconstituents, Zoopharmacognosy, Marine Pharmacognosy etc.,

The worldwide business sector for plant and plant medications was estimated at $23.2 billion in 2013 and $24.4 billion in 2014. This aggregate business sector is expected to reach $25.6 billion in 2015 and almost $35.4 billion in 2020, with a compound annual growth rate (CAGR) of 6.6% between 2015 and 2020.

  • Track 3-1Medical Plants and Toxic Plants
  • Track 3-2Natural Products and Plant Extracts
  • Track 3-3Phytoconstituents
  • Track 3-4Phytopharmacological Activities
  • Track 3-5Medicinal and Aromatic Plants
  • Track 3-6Essential oils and pure isolates
  • Track 3-7Biological evaluation of crude extracts
  • Track 3-8Traditional Medicine
  • Track 3-9Herbal Medicine
  • Track 3-10Primary and Secondary Metabolites
  • Track 3-11Ethnobotany and Plant Anatomy
  • Track 3-12Cell and Molecular Plant Biology
  • Track 3-13Natural Products discovery and evaluation
  • Track 3-14Nutraceuticals

Medicinal chemistry and pharmaceutical chemistry are disciplines at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties, where they are involved with design, chemical synthesis and development for market of pharmaceutical agents, or bio-active molecules (drugs). This particular session involves discussion on synthetic and computational aspects of the study of existing drugs and agents in development in relation to their bioactivities (biological activities and properties), i.e., understanding their structure-activity relationships (SAR). Pharmaceutical chemistry is focused on quality aspects of medicines and aims to assure fitness for purpose of medicinal products.

It has been estimated that in the field of Medicinal Chemistry more than $79 million was invested since 2008. A complete review of drug designing market has brought out some significant elements that the business sector has a development with $ 198 Billion between 2008 and 2013 and in further this might increase to $236 Billion from 2014 to 2019.

  • Track 4-1Computational chemistry
  • Track 4-2Structure aided and computer aided drug design
  • Track 4-3Molecular drug design
  • Track 4-4Telemedicine
  • Track 4-5Protein structure prediction and molecular simulation
  • Track 4-6Biochemistry
  • Track 4-7Exploratory development
  • Track 4-8Phytotherapy & Complementary medicine
  • Track 4-9Protein structure prediction and molecular simulation and etc.....

Nanotechnology is being employed in the pharmaceutical field for many reasons, but perhaps the leading goals are to improve drug solubility/bio-availability and/or delivery to various sites of action. Nanotechnology is also being employed to develop new and improved therapeutic devices. Therapeutics are enhanced through both the improved drug delivery, drug targeting and bioavailability of existing medicinal substances, as well as the discovery of entirely new substances and nanomaterials, which introduces a range of advantages over classical drug-delivery methods, including the targeted delivery to diseased sites only, and the improved adsorption, distribution and duration of medicines in the body. Nanotechnology is dealt with discussions on topics like nanomedicine, tissue engineering, nanorobots, biosensors, nanomaterials, biomarkers, image enhancement devices and implant technology.

International nanomedicine market was valued at $214.2 billion in 2013 and $248.3 billion in 2014. The total market is estimated to grow at a compound annual growth rate (CAGR) of 16.3% between 2014 and 2019 and would reach $528 billion by 2019. According to BCC Research, the global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is estimated to grow to more than $79.8 billion by 2019, at a  compound annual growth rate (CAGR) of 22%. The highest increase will come in the area of drug delivery systems.

  • Track 5-1Nanomedicine
  • Track 5-2Nano particles in drug delivery
  • Track 5-3Pharmaceutical nanotechnology
  • Track 5-4Nanotechnology drug delivery systems
  • Track 5-5Nanotechnology and therapeutic delivery
  • Track 5-6Applications of nanotechnology

Drugs are not ordinary consumers’ products. In most instances, consumers are not in a position to make decisions about when to use drugs, which drugs to use, how to use them and to weigh potential benefits against risks as no medicine is completely safe. Professional advice from either prescribers or dispensers is needed in making these decisions. The topics in this session include Regulations and organizations, Clinical Pharmacy Services: patient compliance, Health care management and providers, implementation of pharmacogenetics in USA, Drug safety, and Drug rediscovery, multiple drug use, Good governance in pharmacy and etc.......

The International regulatory affairs market is showcasing a CAGR of 14.6% between the period of 2014 and 2020. The market’s value was US$1.56 bn by 2013. It is forecasted that, the global regulatory affairs outsourcing market will be valued at US$4.49 bn by the end of 2020 according to a research report by Transparent Market Research. 

  • Track 6-1Regulations and organizations
  • Track 6-2Online pharmacies
  • Track 6-3Multiple drug use
  • Track 6-4Halal medication
  • Track 6-5Role of pharmacists
  • Track 6-6Pharmaceutical services
  • Track 6-7Drug rediscovery
  • Track 6-8Drug safety
  • Track 6-9Implimentation of pharmacogenetics in USA
  • Track 6-10Health care management and providers
  • Track 6-11Clinical Pharmacy Services: patient compliance
  • Track 6-12Good governance in pharmacy and etc.......

By definition Industrial Pharmacy is a discipline which includes manufacturing, development, marketing and distribution of drug products including quality assurance of these activities. This broad research area relates to different functions in pharmaceutical industry and having contact areas with engineering and economics.

Pharmacy practice is the discipline of pharmacy which involves developing the professional roles of pharmacists. Disease-state management, Clinical interventions (refusal to dispense a drug, recommendation to change and/or add a drug to a patient's pharmacotherapy, dosage adjustments, Professional development, Pharmaceutical care, Extemporaneous pharmaceutical compounding, Patient care, Drug abuse prevention, Prevention of drug interactions, including drug-drug interactions or drug-food interactions, Prevention (or minimization) of adverse events, Incompatibility, Drug discovery and evaluation, Community Pharmacy etc,.

 The International generic drugs sector reached $269.8 billion by 2012. This sector is estimated to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a consistent compound annual growth rate (CAGR) of 11.5%. 

  • Track 7-1Drug discovery and development
  • Track 7-2Good manufacturing practices
  • Track 7-3Post- marketing surveillance
  • Track 7-4Product management
  • Track 7-5Waste management
  • Track 7-6Supply chain management
  • Track 7-7Clinical studies
  • Track 7-8Pre-clinical studies
  • Track 7-9Industrial pharmaceutics
  • Track 7-10Pharmacovigilance and clinical trials

Genetics is the Science of genes, genetic variation and heredity living beings. It is generally considered as a field of biology, but it is mostly an Interdisciplinary Science which involves with many of the life sciences and is potentially related with the study of information systems. Biomedical Engineering is the application of Engineering principles and design concepts to drugs and biology for an emerging healthcare Industries like diagnostics and therapeutics. This Science has filled the gap between engineering and medicine: It adds the advantages of the problem solving skills and design of engineering with medical and biological sciences to improve health care treatment.

The International genome editing market is estimated to reach $3,514.08 Million by 2019 from $1,845.25 Million in 2014, at a growing CAGR of 13.75%. This is mainly due to the growth of biotechnology and demand in pharmaceutical R&D, along with advances in technology.

  • Track 8-1Genomics and proteomics in Pharmaceutical Industry
  • Track 8-2Clinical engineering in Pharmaceutical Industry
  • Track 8-3Tissue engineering in Pharmaceutical Industry
  • Track 8-4Identification and classification of genes
  • Track 8-5Bio-engineering in Pharmaceutical Industry
  • Track 8-6Engineering models in biomedicine
  • Track 8-7Bionic human
  • Track 8-8Clinical laboratory sciences
  • Track 8-9Biomedical data engineering and etc......

The philosophy of pharmacy practice acknowledges pharmacists as health professionals with the knowledge, skills and attributes to take responsibility for the management and utilisation of medicines, in order to optimise medicines related health outcomes. Pharmacy practice includes the technical aspects of pharmacy services, preparation of pharmaceuticals and medicines supply management as well as patient-centred care with counselling, providing drug information and monitoring drug therapy.

After a few ups and downs in last years, International prescription drug sales is estimated to show a growth at 4.8% annually over the next five years, and would reach $987 billion by 2020.This statistic depicts a projection for the total prescription drug revenue worldwide between 2015 and 2020. In 2018, the industry is expected to generate $872 billion U.S. dollars in prescription drug revenue from all over the world. 

  • Track 9-1FDCA
  • Track 9-2NDA
  • Track 9-3Adulteration
  • Track 9-4Misbranding
  • Track 9-5Exemption in prescription
  • Track 9-6Experimental animal ethics
  • Track 9-7Human trial ethics and etc....

Preformulation studies are an essential component of drug development wherein it supports development of formulations, for different stages of clinical trials. The word preformulation is composed of two words pre and formulation. Activities done prior to formulation development are called as preformulation studies. It provides the scientific basis for formulation development. Topics discussed in this session are Solubility, dissociation constant (pKa), salt formation, partition or distribution coefficient (log P or log D), pH solubility profile and dissolution kinetics, polymorphism, solvated forms and amorphous form and solid state stability and solution state stability, characterization of particle properties like morphology ,bulk density, flow properties and compaction behavior.

According to the report, the International active pharmaceuticals ingredients (APIs) market is estimated to expand at a moderate CAGR of 6.5% from 2014 to 2020. The global active pharmaceuticals ingredients market was valued at US$119.7 bn in 2013  and the market is estimated to be worth US$185.9 bn by 2020. 

  • Track 10-1Material characterisation - chemical and physical
  • Track 10-2Morphic form identification
  • Track 10-3Salt selection
  • Track 10-4Compressibility testing
  • Track 10-5Excipient and Process compatibility testing and etc....

Clinical pharmacy is the branch of pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness and disease prevention.This session deals with topics likebasic components of clinical pharmacy practice Prescribing drugs , Administering drugs, Documenting professional services, Reviewing drug use, Counselling, Consulting, Preventing Medication Errors etc.,

The International market of pharmacy automation has shown a growth from $2.1 billion in 2006 to $2.3 billion in 2007. It was forecasted that by 2012, the inpatient pharmacy automation market is estimated to be worth nearly $2.9 billion, a CAGR of 9.8%. The outpatient pharmacy automation system will continue to show moderate growth through 2012, with a CAGR of 7.8% for the next 5 years. 

  • Track 11-1Drug interactions and adverse drug reactions
  • Track 11-2Advances in Clinical Pharmacy
  • Track 11-3Pharmacy Practice and Pharmacoeconomy
  • Track 11-4Pharmacoepidimiology and Pharmacotherapy
  • Track 11-5Clinical Immunology
  • Track 11-6Clinical molecular genetics
  • Track 11-7Clinical drug development and therapeutics
  • Track 11-8Clinical pharmacy and its key role in treatment
  • Track 11-9Role of clinical pharmacist
  • Track 11-10Research methodology and recent updates on clinical trials

Green chemistry, also called sustainable chemistry, is a philosophy of chemical research and engineering that encourages the design of products and processes that minimize the use and generation of hazardous substances. As a chemical philosophy, green chemistry applies to organic chemistry, inorganic chemistry, biochemistry, analytical chemistry, physical chemistry and even chemical engineering.

One research report says that the green chemistry market is estimated to grow from $2.8bn in 2011 to $98.5bn by 2020. Others reposts are even more bullish, forecasting growth in the bio-based chemicals market from $78bn in 2012 to $198bn in 2017, eventually resulting for 50% of the chemicals market by 2050. Pike Research predicts the current size of the green chemical industry is approximately at $2.8 billion worldwide. It will likely grow to about $11.0 billion in 2015 and nearly $100 billion in 2020. 

  • Track 12-1Solvent Use and Waste Issues
  • Track 12-2Solvent Use and Waste Issues
  • Track 12-3Environmental and Regulatory Aspects
  • Track 12-4Green Technologies in the Pharmaceutical Industry
  • Track 12-5Future Trends for Green Chemistry in the Pharmaceutical Industry

Pharmaceutical Microbiology is an applied branch of Microbiology. It involves the study of microorganisms associated with the manufacture of pharmaceuticals e.g. minimizing the number of microorganisms in a process environment, excluding microorganisms and microbial by-products like exotoxin and endotoxin from water and other starting materials, and ensuring the finished pharmaceutical product is sterile. This session includes discussions on aspects of pharmaceutical microbiology include the research and development of anti-infective agents, the use of microorganisms to detect mutagenic and carcinogenic activity in prospective drugs, and the use of microorganisms in the manufacture of pharmaceutical products like insulin and human growth hormone.

According to a report the global market for biotechnology, is estimated to grow at an average annual growth rate of CAGR 11.6% between 2012 and 2017 and reach a worth of $414.5 billion by 2017. This market was valued around $216.5 billion in 2011.

  • Track 13-1Antimicrobial activity
  • Track 13-2Disinfectants
  • Track 13-3Cleanrooms and controlled environments
  • Track 13-4Microbial Contamination
  • Track 13-5Recombinant DNA technology

Marketing of Pharmaceuticals is also called medico-marketing or pharma marketing in most countries, is the business of advertising or promoting the sales of pharmaceuticals or medicines. Many countries have measures in their respective places with limits for advertising by pharmaceutical companies.

Pharmaceutical companies are spending on marketing is excess to that of its research budget. In 2004 Canada spent $1.7 billion for marketing drugs to physicians; whereas United States had spent $21 billion in 2002. In 2005, United States expenditure on pharmaceutical marketing was estimated at $29.9 billion. 

The Pharma Industry bears the responsibility for drugs development, production and their marketing. An international research company, IMS Health Consulting assumes that the size of the global pharmaceutical market in 2012 has reached $940 billion. In simple terms it had expanded by 6%. They have projected a growth of not less than 3% to 4% a year in the coming future and if it is to happen the global pharmaceutical market is estimated to reach $1.1 trillion by 2015 and would reach $1.2 trillion in 2016 and around $1.5 trillion by 2020. 

Pharma Middle East 2016 is a platform that targets to connect Entrepreneurs, decision makers and the Investors worldwide. It is intended to create and facilitate the most optimized and viable meeting place for involving people in International business discussions, execution and evaluation of promising business ideas. An investor could be able to find out a lot of potential investment opportunities worldwide, which provide good return on their investments. This would be an ideal place and great opportunity for entrepreneurs to reach out suitable investors and partners to start or expand their business. Hence this is a perfect place to connect Business Owners, Entrepreneurs, Established Corporates and Early Stage Companies with National or International Investors, Corporate Investors and Potential Business Partners.

The Pharma Industry bears the responsibility for drugs development, production and their marketing. An international research company, IMS Health Consulting assumes that the size of the global pharmaceutical market in 2012 has reached $940 billion. In simple terms it had expanded by 6%. They have projected a growth of not less than 3% to 4% a year in the coming future and if it is to happen the global pharmaceutical market is estimated to reach $1.1 trillion by 2015 and would reach $1.2 trillion in 2016 and around $1.5 trillion by 2020.